

Natsar Pharmaceuticals Announces Presentation and Partnering Discussions at Biotech Showcase™ 2026 during J.P. Morgan Healthcare Week

January 8, 2026 – Ellicott City, MD – Natsar Pharmaceuticals, Inc., a late pre-clinical stage company developing targeted oncology therapeutic RK-33, will present its latest developments at the Biotech Showcase in San Francisco from January 12-14, 2026.

Natsar's leadership will share recent company milestones and research developments for lead product RK-33, a first in class DDX3 inhibitor for solid tumors. Natsar is currently raising Series A funds to initiate its Phase 1 program within 2026.

"We are excited to engage with investors and strategic partners who share our vision of transforming outcomes for patients with aggressive cancers," said Dr. Venu Raman, Founder & CSO of Natsar. "This represents a time-limited opportunity for investors to join us at this pivotal inflection point as we transition from pre-clinical development to clinical validation. We aim to make investors part of our future as RK-33 advances into the clinic."

RK-33 works by blocking a protein that cancer cells need to survive and grow, and preclinical studies show it can fight multiple types of aggressive cancers while leaving healthy cells unharmed.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that foster investment and partnership opportunities.

Details of the Natsar presentation are as follows:

- **Event:** Biotech Showcase 2026, Hilton San Francisco - Union Square
- **Date:** Monday, January 12, 2026
- **Time:** 3:15 PM
- **Track:** Franciscan C (Ballroom Level)

Natsar leadership will be available following the presentation for one-on-one meetings with investors and potential partners.

To learn more about the event, please visit <https://informaconnect.com/biotech-showcase> or to schedule one-on-one meetings, please email: investors@natsarpharma.com.

About RK-33

RK-33 is a first-in-class inhibitor of DDX3, an RNA helicase that plays a key role in tumor cell survival and proliferation. DDX3 is overexpressed in many aggressive cancers, where it supports essential processes such as DNA repair, signaling, motility, and energy regulation. By inhibiting DDX3, RK-33 disrupts multiple oncogenic pathways simultaneously, leading to selective tumor cell death while sparing normal cells.

In preclinical studies, RK-33 has demonstrated broad anti-tumor activity across multiple models, including sarcoma, brain tumors, pancreatic cancer, lung cancer, and breast cancer bone metastasis. Importantly, RK-33 also acts as a potent radiosensitizer, enhancing the effectiveness of radiation therapy and creating opportunities for use in combination with standard-of-care regimens.

About Natsar Pharmaceuticals, Inc.

Natsar Pharmaceuticals is a privately held U.S.-based pharmaceutical company dedicated to developing innovative therapies for cancer and other serious diseases. The company's lead program, RK-33, is a novel small molecule that targets DDX3, an RNA helicase implicated in multiple aggressive and metastatic cancers. With strong preclinical evidence of efficacy and a differentiated mechanism of action, RK-33 is now being advanced by Natsar into Phase 1 clinical trials.